Cargando…

HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor

PURPOSE: Human epidermal growth factor receptor 2 (HER2) status is both an independent prognostic factor and a predictive factor for the efficacy of targeted therapy for breast cancer, so it is critical to accurately detect HER2 protein expression and/or gene amplification. According to the recommen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yuanyuan, Wu, Shafei, Shi, Xiaohua, Luo, Yufeng, Pang, Junyi, Wang, Changjun, Mao, Feng, Liang, Zhiyong, Zeng, Xuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Preclinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797640/ https://www.ncbi.nlm.nih.gov/pubmed/31388934 http://dx.doi.org/10.1007/s10549-019-05387-6

Ejemplares similares

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Breast Cancer With a HER2 IHC2+ and FISH HER2/CEP17 Ratio ≥2.0 and an Average HER2 Gene Copy Number <4.0 per Tumor Cell: HER2 mRNA Overexpression Is a Rare Event
por: Liu, Yuanyuan, et al.
Publicado: (2020)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy
por: Crespo, James, et al.
Publicado: (2020)

The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment
por: Marchiò, Caterina, et al.
Publicado: (2018)

A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression
por: Reix, Nathalie, et al.
Publicado: (2016)

Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
por: Li, Kai, et al.
Publicado: (2020)

Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis
por: Wang, Yuefeng, et al.
Publicado: (2017)

Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2018)

Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
por: Agersborg, Sally, et al.
Publicado: (2018)

Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines
por: Press, Michael F., et al.
Publicado: (2018)

Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors
por: Yeh, Elizabeth S., et al.
Publicado: (2014)

Evaluation of ERBB2 mRNA Expression in HER2-Equivocal (2+) Immunohistochemistry Cases
por: Carretero-Barrio, Irene, et al.
Publicado: (2023)

Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program
por: Bilous, Michael, et al.
Publicado: (2012)

HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies
por: Tracey, Natasha, et al.
Publicado: (2019)

The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer
por: Eustace, A. J., et al.
Publicado: (2021)

MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer
por: Han, Jinil, et al.
Publicado: (2017)

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples
por: Wilson, Timothy R., et al.
Publicado: (2014)

Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis
por: Lewis Phillips, Gail D., et al.
Publicado: (2017)

Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?
por: Sadanandam, Anguraj, et al.
Publicado: (2012)

The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast Carcinomas
por: Ji, Hongfei, et al.
Publicado: (2015)

The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype
por: Tiainen, Satu, et al.
Publicado: (2020)

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
por: Moreno-Aspitia, Alvaro, et al.
Publicado: (2013)

Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients
por: Liang, Zhiyong, et al.
Publicado: (2008)

Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies
por: Hida, Akira I., et al.
Publicado: (2016)

A83-01 inhibits TGF-β-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells
por: Wu, Yanyuan, et al.
Publicado: (2017)

The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast
por: Narbe, Ulrik, et al.
Publicado: (2019)

Ultrasound and clinicopathological characteristics-based model for prediction of pathologic response to neoadjuvant chemotherapy in HER2-positive breast cancer: a case–control study
por: Sui, Lin, et al.
Publicado: (2023)

The prognostic and predictive role of tumor-infiltrating lymphocytes (FoxP3 + and CD8 +) and tumor-associated macrophages in early HER2 + breast cancer
por: Jääskeläinen, Minna M., et al.
Publicado: (2023)

Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline
por: Kong, Hui, et al.
Publicado: (2022)

Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients
por: Zhao, Xiangshan, et al.
Publicado: (2012)

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)
por: Perez, Edith A., et al.
Publicado: (2013)

Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer
por: Fiascarelli, Alessio, et al.
Publicado: (2023)

Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer
por: Gupta, Swati, et al.
Publicado: (2019)

Comparative Study between Quantitative Digital Image Analysis and Fluorescence In Situ Hybridization of Breast Cancer Equivocal HER2 2+ Cases
por: Ayad, E., et al.
Publicado: (2014)

Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform
por: Wu, Natalie C., et al.
Publicado: (2018)

Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification
por: Ercolani, Cristiana, et al.
Publicado: (2017)

Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict)
por: Jank, Paul, et al.
Publicado: (2021)

Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results
por: Wang, Bo, et al.
Publicado: (2019)

HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens
por: Nishimura, Rieko, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_v67quvbmkv8m5rql5m3n78k8nk